{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:38:46Z","timestamp":1793342326542,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200245, 82104447, 82302641"],"award-info":[{"award-number":["82200245, 82104447, 82302641"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200245, 82104447, 82302641"],"award-info":[{"award-number":["82200245, 82104447, 82302641"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Lung cancer, particularly non-small cell lung cancer (NSCLC), has high recurrence rates and remains a leading cause of cancer-related death, despite recent advances in its treatment. Emerging therapies, such as chimeric antigen receptor (CAR)-T cell therapy, have shown promise but face significant challenges in targeting solid tumors. This study investigated the potential of combining receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeting CAR-T cells with ferroptosis inducers to promote ferroptosis of tumor cells and enhance anti-tumor efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>RNA-seq data and immunofluorescence analysis of relapsed NSCLC patient samples were used to explore ROR1 expression. In addition, ROR1-targeting CAR-T cells were developed to assess cytotoxic activity against ROR1<jats:sup>+<\/jats:sup> tumor cells, and the effect of cytokine stimulation on their efficacy was evaluated. Lipidomics, immunofluorescent histochemistry, and western blotting were used to explore the observed effects. Ferroptosis indicators, including levels of reactive oxygen species, were used to detect the combined effect of CAR-T cells and ferroptosis-inducing drugs. Finally, tumor-bearing mice were used to validate the in vivo efficacy of the combination therapy strategy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Tumor cells treated with ferroptosis inducers showed increased sensitivity to Interferon gamma (IFN-\u03b3) secreted by ROR1 CAR-T cells. Furthermore, ROR1 CAR-T cells enhanced the production of phosphatidylcholine with diacyl-polyunsaturated fatty acid tails (PC-PUFA2) by working in tandem with IFN-\u03b3. This enhancement promoted the expression of acyl-CoA synthetase long chain family member 4 (ACSL4), which in turn strengthened the overall anti-tumor response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Combining ROR1 CAR-T cells with ferroptosis inducers enhanced anti-tumor efficacy in NSCLC by promoting ferroptosis through increased lipid peroxidation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40364-025-00730-0","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T10:46:17Z","timestamp":1737629177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-4133","authenticated-orcid":false,"given":"Dan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xumin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-3990","authenticated-orcid":false,"given":"Zhenshu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1688-2864","authenticated-orcid":false,"given":"Jiayi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"3","key":"730_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"730_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-024-01587-w","volume":"17","author":"D Liu","year":"2024","unstructured":"Liu D, Wu L, Xu X, Yang S, Liu M, Hu M, et al. Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting. J Hematol Oncol. 2024;17(1):84.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"730_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.critrevonc.2015.03.001","volume":"95","author":"A Arcaro","year":"2015","unstructured":"Arcaro A. Targeted therapies for small cell lung cancer: where do we stand? Crit Rev Oncol Hematol. 2015;95(2):154\u201364.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"730_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40.","journal-title":"Mol Cancer"},{"issue":"7689","key":"730_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354.","journal-title":"Nature"},{"issue":"7","key":"730_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.21037\/tlcr-21-1028","volume":"11","author":"JK Yun","year":"2022","unstructured":"Yun JK, Lee GD, Choi S, Kim YH, Kim DK, Park SI, et al. Various recurrence dynamics for non-small cell lung cancer depending on pathological stage and histology after surgical resection. Transl Lung Cancer Res. 2022;11(7):1327\u201336.","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"730_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","volume":"73","author":"RH Parikh","year":"2023","unstructured":"Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023;73(3):275\u201385.","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"730_CR8","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"3","key":"730_CR9","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.7150\/thno.66832","volume":"12","author":"D Li","year":"2022","unstructured":"Li D, Wang W, Xie S, Ge M, Wang R, Xu Q, et al. A T-cell independent universal cellular therapy strategy through antigen depletion. Theranostics. 2022;12(3):1148\u201360.","journal-title":"Theranostics"},{"issue":"1","key":"730_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","volume":"13","author":"X Gu","year":"2024","unstructured":"Gu X, Zhang Y, Zhou W, Wang F, Yan F, Gao H, et al. Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers. Exp Hematol Oncol. 2024;13(1):70.","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"730_CR11","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","volume":"12","author":"RM Young","year":"2022","unstructured":"Young RM, Engel NW, Uslu U, Wellhausen N, June CH. Next-generation CAR T-cell therapies. Cancer Discov. 2022;12(7):1625\u201333.","journal-title":"Cancer Discov"},{"issue":"1","key":"730_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21(1):47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"730_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20(7):531\u201350.","journal-title":"Nat Rev Drug Discov"},{"key":"730_CR14","doi-asserted-by":"crossref","unstructured":"Jo Y, Ali LA, Shim JA, Lee BH, Hong C. Innovative CAR-T cell therapy for solid tumor; current duel between CAR-T Spear and Tumor Shield. Cancers (Basel). 2020;12(8).","DOI":"10.3390\/cancers12082087"},{"issue":"8","key":"730_CR15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu U, Castelli S, June CH. CAR T cell combination therapies to treat cancer. Cancer Cell. 2024;42(8):1319\u201325.","journal-title":"Cancer Cell"},{"issue":"6","key":"730_CR16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35(6):830\u201349.","journal-title":"Cancer Cell"},{"issue":"5","key":"730_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280\u201396.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"730_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"730_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-024-01564-3","volume":"17","author":"F Chen","year":"2024","unstructured":"Chen F, Kang R, Tang D, Liu J. Ferroptosis: principles and significance in health and disease. J Hematol Oncol. 2024;17(1):41.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"730_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41420-022-01297-7","volume":"8","author":"Y Du","year":"2022","unstructured":"Du Y, Guo Z. Recent progress in ferroptosis: inducers and inhibitors. Cell Death Discov. 2022;8(1):501.","journal-title":"Cell Death Discov"},{"issue":"7","key":"730_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381\u201396.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"730_CR22","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","volume":"23","author":"A Balakrishnan","year":"2017","unstructured":"Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, et al. Analysis of ROR1 protein expression in Human Cancer and normal tissues. Clin Cancer Res. 2017;23(12):3061\u201371.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"730_CR23","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood.2021014760","volume":"140","author":"TJ Kipps","year":"2022","unstructured":"Kipps TJ. ROR1: an orphan becomes apparent. Blood. 2022;140(14):1583\u201391.","journal-title":"Blood"},{"key":"730_CR24","doi-asserted-by":"crossref","unstructured":"Tran TM, Chand Thakuri BK, Nurmukhambetova S, Lee JJ, Hu P, Tran NQ et al. Armored TGF\u03b2RIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGF\u03b21. J Immunother Cancer. 2024;12(4).","DOI":"10.1136\/jitc-2023-008261"},{"issue":"2","key":"730_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.immuni.2018.02.010","volume":"48","author":"SC Jameson","year":"2018","unstructured":"Jameson SC, Masopust D. Understanding subset diversity in T cell memory. Immunity. 2018;48(2):214\u201326.","journal-title":"Immunity"},{"key":"730_CR26","doi-asserted-by":"publisher","first-page":"215710","DOI":"10.1016\/j.canlet.2022.215710","volume":"538","author":"L Shen","year":"2022","unstructured":"Shen L, Xiao Y, Zhang C, Li S, Teng X, Cui L, et al. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity. Cancer Lett. 2022;538:215710.","journal-title":"Cancer Lett"},{"issue":"1\u20132","key":"730_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1\u20132):317\u201331.","journal-title":"Cell"},{"issue":"5","key":"730_CR28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41589-020-0501-5","volume":"16","author":"JK Eaton","year":"2020","unstructured":"Eaton JK, Furst L, Ruberto RA, Moosmayer D, Hilpmann A, Ryan MJ, et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat Chem Biol. 2020;16(5):497\u2013506.","journal-title":"Nat Chem Biol"},{"issue":"5","key":"730_CR29","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2024.01.030","volume":"187","author":"B Qiu","year":"2024","unstructured":"Qiu B, Zandkarimi F, Bezjian CT, Reznik E, Soni RK, Gu W, et al. Phospholipids with two polyunsaturated fatty acyl tails promote ferroptosis. Cell. 2024;187(5):1177\u2013e9018.","journal-title":"Cell"},{"issue":"7755","key":"730_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, Green M, Choi JE, Gij\u00f3n M, Kennedy PD, Johnson JK, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270\u20134.","journal-title":"Nature"},{"issue":"4","key":"730_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","volume":"40","author":"P Liao","year":"2022","unstructured":"Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y, et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40(4):365\u2013e786.","journal-title":"Cancer Cell"},{"issue":"1","key":"730_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91\u20138.","journal-title":"Nat Chem Biol"},{"issue":"12","key":"730_CR33","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1158\/2326-6066.CIR-24-0130","volume":"12","author":"Y Gao","year":"2024","unstructured":"Gao Y, Liu S, Huang Y, Wang H, Zhao Y, Cui X, et al. CAR T cells Engineered to secrete IFN\u03ba induce Tumor Ferroptosis via an IFNAR\/STAT1\/ACSL4 Axis. Cancer Immunol Res. 2024;12(12):1691\u2013702.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"730_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41423-021-00735-3","volume":"19","author":"W Du","year":"2022","unstructured":"Du W, Frankel TL, Green M, Zou W. IFN\u03b3 signaling integrity in colorectal cancer immunity and immunotherapy. Cell Mol Immunol. 2022;19(1):23\u201332.","journal-title":"Cell Mol Immunol"},{"issue":"34","key":"730_CR35","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1038\/s41388-022-02416-5","volume":"41","author":"H Peng","year":"2022","unstructured":"Peng H, Nerreter T, Mestermann K, Wachter J, Chang J, Hudecek M, et al. ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene. 2022;41(34):4104\u201314.","journal-title":"Oncogene"},{"issue":"12","key":"730_CR36","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s11427-024-2685-9","volume":"67","author":"L Li","year":"2024","unstructured":"Li L, Huang W, Ren X, Wang Z, Ding K, Zhao L, et al. Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies. Sci China Life Sci. 2024;67(12):2603\u201316.","journal-title":"Sci China Life Sci"},{"issue":"24","key":"730_CR37","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1182\/blood.2020008404","volume":"137","author":"T Vaisitti","year":"2021","unstructured":"Vaisitti T, Arruga F, Vitale N, Lee TT, Ko M, Chadburn A, et al. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021;137(24):3365\u201377.","journal-title":"Blood"},{"issue":"1","key":"730_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"issue":"14","key":"730_CR39","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhou Z, Dang Q, Xu H, Lv J, Li H, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022;12(14):6273\u201390.","journal-title":"Theranostics"},{"issue":"5","key":"730_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ajh.26486","volume":"97","author":"X Shi","year":"2022","unstructured":"Shi X, Yan L, Shang J, Kang L, Yan Z, Jin S, et al. Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol. 2022;97(5):537\u201347.","journal-title":"Am J Hematol"},{"issue":"2","key":"730_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death Nexus linking metabolism, Redox Biology, and Disease. Cell. 2017;171(2):273\u201385.","journal-title":"Cell"},{"issue":"1","key":"730_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nchembio.2238","volume":"13","author":"VE Kagan","year":"2017","unstructured":"Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81\u201390.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"730_CR43","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cell.2017.09.044","volume":"171","author":"SE Wenzel","year":"2017","unstructured":"Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell. 2017;171(3):628\u2013e4126.","journal-title":"Cell"},{"issue":"6","key":"730_CR44","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41418-020-00719-2","volume":"28","author":"X Luo","year":"2021","unstructured":"Luo X, Gong HB, Gao HY, Wu YP, Sun WY, Li ZQ, et al. Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. Cell Death Differ. 2021;28(6):1971\u201389.","journal-title":"Cell Death Differ"},{"key":"730_CR45","doi-asserted-by":"crossref","unstructured":"Lu C, Zhou X, Zhang L. Phospholipids with two polyunsaturated fatty acyl tails: an important driver of ferroptosis. MedComm (2020). 2024;5(7):e606.","DOI":"10.1002\/mco2.606"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00730-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00730-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00730-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:21:27Z","timestamp":1737631287000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00730-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00730-0","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human tissue and blood samples were collected after written informed consent was obtained. The study protocol was approved by the Ethics Committee of Shanghai Chest Hospital with license number KS23027. All xenograft mouse model experiments were approved by the Institutional Animal Care and Use Committee at Shanghai Chest Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}